P-cadherin promotes cervical cancer growth and invasion through affecting the expression of E-cadherin and p120 catenin

Objective: The aim of the present study was to investigate the role of P-cadherin in cervical carcinogenesis and cancer progression. Materials and Methods: The expression of placental cadherin (P-cadherin) protein was examined by Western blot in different cervical samples and cervical cell lines. Through regulating P-cadherin expression in Siha or 293T cells, cell growth, migration, and invasion were examined separately using a cell-counting kit-8 (CCK-8) or Transwell assays, and meanwhile the expression of cadherin/catenin complex was tested using Western blot. Results: Western blot showed that P-cadherin was overexpressed in cervical cancer tissues and cancer-derived cell lines compared with normal cervical tissues. Silencing P-cadherin expression resulted in increase of epithelial cadherin (E-cadherin) and decrease of p120 catenin (p120ctn) expression, which was accompanied by inhibiting cell growth and reducing cell migration and invasion. Conversely, overexpression of P-cadherin led to downregulation of E-cadherin and upregulation of p120ctn expression, which was accompanied by promoting cell growth and increasing cell migration and invasion. Conclusions: P-cadherin could promote cervical cancer growth and invasion, at least partly through affecting the expression of E-cadherin and p120 catenin, consequently contributing to cervical carcinogenesis and cancer progression.

P-cadherin; E-cadherin; p120ctn; Metastasis; Cervical cancer

[1] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: “Global Cancer Statistics”. CA Cancer J. Clin., 2015, 65, 87.

[2] Moody C.A., Laimins L.A.: “Human papillomavirus oncoproteins: pathways to transformation”. Nat. Rev. Cancer, 2010, 10, 550.

[3] Biewenga P., van der Velden J., Mol B.W., Stalpers L.J., Schilthuis M.S., van der Steeg J.W., et al.: “Prognostic model for survival in patients with early stage cervical cancer”. Cancer, 2011, 117, 768.

[4] Landoni F., Maneo A., Colombo A., Placa F., Milani R., Perego P., et al.: “Randomised study of radical surgery versus radiotherapy for stage IbIIa cervical cancer”. Lancet, 1997, 350, 535.

[5] Hirai Y., Nose A., Kobayashi S., Takeichi M.: “Expression and role of E- and P-cadherin adhesion molecules in embryonic histogenesis. II. Skin morphogenesis”. Development, 1989, 105, 271.

[6] Radice G.L., Ferreira-Cornwell M.C., Robinson S.D., Rayburn H., Chodosh L.A., Takeichi M., et al.: “Precocious mammary gland development in P-cadherin-deficient mice”. J. Cell. Biol., 1997, 139, 1025.

[7] Paredes J., Figueiredo J., Albergaria A., Oliveira P., Carvalho J., Ribeiro A.S., et al.: “Epithelial E- and P-cadherins: role and clinical significance in cancer”. Biochim Biophys. Acta, 2012, 1826, 297.

[8] Mandeville J.A., Silva Neto B., Vanni A.J., Smith G.L., Rieger-Christ K.M., Zeheb R., et al.: “P-cadherin as a prognostic indicator and a modulator of migratory behaviour in bladder carcinoma cells”. BJU Int., 2008, 102, 1707.

[9] Paredes J., Albergaria A., Oliveira J.T., Jerónimo C., Milanezi F., Schmitt F.C.: “P-cadherin overexpression is an indicator of clinical outcome in invasive breast carcinomas and is associated with CDH3 promoter hypomethylation”. Clin. Cancer Res., 2005, 11, 5869.

[10] Sun L., Hu H., Peng L., Zhou Z., Zhao X., Pan J., et al.: “P-cadherin promotes liver metastasis and is associated with poor prognosis in colon cancer”. Am. J. Pathol., 2011, 179, 380.

[11] Li B.H., Zhou J.S., Ye F., Cheng X.D., Zhou C.Y., Lu W.G., et al.: “Reduced miR-100 expression in cervical cancer and precursors and its carcinogenic effect through targeting PLK1 protein”. Eur. J. Cancer, 2011, 47, 2166.

[12] Albergaria A., Ribeiro A.S., Vieira A.F., Sousa B., Nobre A.R., Seruca R., et al.: “P-cadherin role in normal breast development and cancer”. Int. J. Dev. Biol., 2011, 55, 811.

[13] Liu N., Yu Q., Liu T.J., Gebreamlak E.P., Wang S.L., Zhang R.J., et al.: “P-cadherin expression and basal-like subtype in breast cancers”. Med. Oncol., 2012, 29, 2606.

[14] Park J., Park E., Han S.W., Im S.A., Kim T.Y., Kim W.H., et al.: “Down-regulation of P-cadherin with PF-03732010 inhibits cell migration and tumor growth in gastric cancer”. Invest. New Drugs, 2012, 30, 1404.

[15] Milicic A., Harrison L.A., Goodlad R.A., Hardy R.G., Nicholson A.M., Presz M.: “Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo”. Cancer Res., 2008, 68, 7760.

[16] Taniuchi K., Nakagawa H., Hosokawa M., Nakamura T., Eguchi H., Ohigashi H., et al.: “Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases”. Cancer Res., 2005, 65, 3092.

[17] Bachmann I.M., Straume O., Puntervoll H.E., Kalvenes M.B., Ak- slen L.A.: “Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma”. Clin. Cancer Res., 2005, 11, 8606.

[18] Muñoz-Guerra M.F., Marazuela E.G., Fernández-Contreras M.E., Gamallo C.: “P-cadherin expression reduced in squamous cell carcinoma of the oral cavity: an indicatior of poor prognosis”. Cancer, 2005, 103, 960.

[19] Vlahova L., Doerflinger Y., Houben R., Becker J.C., Schrama D., Weiss C., et al.: “P-cadherin expression in Merkel cell carcinomas is associated with prolonged recurrence-free survival”. Br. J. Dermatol., 2012, 166, 1043.

[20] Li B., Shi H., Wang F., Hong D., Lv W., Xie X., et al.: “Expression of E-, P- and N-Cadherin and Its Clinical Significance in Cervical Squamous Cell Carcinoma and Precancerous Lesions”. PLoS One, 2016, 11, e0155910.

[21] Ribeiro A.S., Albergaria A., Sousa B., Correia A.L., Bracke M., Seruca R., et al.: “Extracellular cleavage and shedding of P-cadherin: a mechanism underlying the invasive behaviour of breast cancer cells”. Oncogene, 2010, 29, 392.

[22] Ribeiro A.S., Sousa B., Carreto L., Mendes N., Nobre A.R., Ricardo S., et al.: “P-cadherin functional role is dependent on E-cadherin cellular context: a proof of concept using the breast cancer model”. J. Pathol., 2013, 229, 705.

[23] Rodríguez-Sastre M.A., González-Maya L., Delgado R., Lizano M., Tsubaki G., Mohar A., et al.: “Abnormal distribution of E-cadherin and beta-catenin in different histologic types of cancer of the uterine cervix”. Gynecol. Oncol., 2005, 97, 330.

[24] Koay M.H., Crook M., Stewart C.J.: “Cyclin D1, E-cadherin and beta-catenin expression in FIGO Stage IA cervical squamous carcinoma: diagnostic value and evidence for epithelial-mesenchymal transition”. Histopathology, 2012, 61, 1125.

[25] Paredes J., Correia A.L., Ribeiro A.S., Milanezi F., Cameselle-Teijeiro J., Schmitt F.C.: “Breast carcinomas that co-express E- and P- cadherin are associated with p120-catenin cytoplasmic localisation and poor patient survival”. J. Clin. Pathol., 2008, 61, 856.

[26] Cheung L.W., Mak A.S., Cheung A.N., Ngan H.Y., Leung P.C., Wong A.S.: “P-cadherin cooperates with insulin-like growth factor-1 receptor to promote metastatic signaling of gonadotropin-releasing hormone in ovarian cancer via p120 catenin”. Oncogene, 2011, 30, 2964.

[27] Jacobs K., Van Gele M., Forsyth R., Brochez L., Vanhoecke B., De Wever O., et al.: “P-cadherin counteracts myosin II-B function: implications in melanoma progression”. Mol. Cancer, 2010, 9, 255.

[28] Lee M.Y., Chou C.Y., Tang M.J., Shen M.R.: “Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-reg- ulation”. Clin. Cancer Res., 2008, 14, 4743.

[29] Cheng Y., Zhou Y., Jiang W., Yang X., Zhu J., Feng D., et al.: “Sig- nificance of E-cadherin, β-catenin, and vimentin expression as post-operative prognosis indicators in cervical squamous cell carcinoma”. Hum. Pathol., 2012, 43, 1213.

[30] Kourtidis A, Ngok SP, Anastasiadis PZ: “p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression”. Prog. Mol. Biol. Transl. Sci., 2013, 116, 409.